Isis Pharma Announces Final Phase 2 Data on ISIS-GCGR Rx Showing Significant Reduction in HbA1c for Type-2 Diabetes Patients

Isis Pharmaceuticals, Inc. ISIS announced today the final results from its Phase 2 study of ISIS-GCGR[Rx] in patients with type 2 diabetes uncontrolled on stable metformin therapy.  In this study, patients in the per protocol population (PP) treated with ISIS-GCGR[Rx] in addition to metformin achieved absolute mean reduction in hemoglobin A1c (HbA1c) of up to 2.25 percentage points from baseline after only 13 weeks of treatment.  Patients receiving placebo had an 0.25 percentage point reduction in HbA1c.  In this study, more than half of the PP patients achieved an HbA1c level of less than or equal to 7.0 percent.  PP patients treated with ISIS-GCGR[Rx] in this study also achieved a mean reduction of up to 74.9 µmol/L in fructosamine.  In addition, in these patients a mean increase in total GLP-1 of up to 19.97 pmol/L was observed.